Metabolic dysfunction-associated steatotic liver disease : An opportunity for collaboration between cardiology and hepatology
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved..
Altered metabolic function has many detrimental effects on the body that can manifest as cardiovascular and liver diseases. Traditional approaches to understanding and treating metabolic dysfunction-associated disorders have been organ-centered, leading to silo-type disease care. However, given the broad impact that systemic metabolic dysfunction has on the human body, approaches that simultaneously involve multiple medical specialists need to be developed and encouraged to optimize patient outcomes. In this review, we highlight how several of the treatments developed for cardiac care may have a beneficial effect on the liver and vice versa, suggesting that there is a need to target the disease process, rather than specifically target the cardiovascular or liver specific sequelae of metabolic dysfunction.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:392 |
|---|---|
| Enthalten in: |
Atherosclerosis - 392(2024) vom: 16. März, Seite 117523 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Raggi, Paolo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Diabetes mellitus |
|---|
| Anmerkungen: |
Date Revised 24.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.atherosclerosis.2024.117523 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370117328 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370117328 | ||
| 003 | DE-627 | ||
| 005 | 20240325235700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.atherosclerosis.2024.117523 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1347.xml |
| 035 | |a (DE-627)NLM370117328 | ||
| 035 | |a (NLM)38522165 | ||
| 035 | |a (PII)S0021-9150(24)00083-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Raggi, Paolo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolic dysfunction-associated steatotic liver disease |b An opportunity for collaboration between cardiology and hepatology |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Altered metabolic function has many detrimental effects on the body that can manifest as cardiovascular and liver diseases. Traditional approaches to understanding and treating metabolic dysfunction-associated disorders have been organ-centered, leading to silo-type disease care. However, given the broad impact that systemic metabolic dysfunction has on the human body, approaches that simultaneously involve multiple medical specialists need to be developed and encouraged to optimize patient outcomes. In this review, we highlight how several of the treatments developed for cardiac care may have a beneficial effect on the liver and vice versa, suggesting that there is a need to target the disease process, rather than specifically target the cardiovascular or liver specific sequelae of metabolic dysfunction | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a Fatty liver disease | |
| 650 | 4 | |a Metabolic syndrome | |
| 650 | 4 | |a Obesity | |
| 650 | 4 | |a Steatohepatitis | |
| 650 | 4 | |a Steatosis | |
| 700 | 1 | |a Milic, Jovana |e verfasserin |4 aut | |
| 700 | 1 | |a Manicardi, Marcella |e verfasserin |4 aut | |
| 700 | 1 | |a Cinque, Felice |e verfasserin |4 aut | |
| 700 | 1 | |a Swain, Mark G |e verfasserin |4 aut | |
| 700 | 1 | |a Sebastiani, Giada |e verfasserin |4 aut | |
| 700 | 1 | |a Guaraldi, Giovanni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Atherosclerosis |d 1970 |g 392(2024) vom: 16. März, Seite 117523 |w (DE-627)NLM000087394 |x 1879-1484 |7 nnns |
| 773 | 1 | 8 | |g volume:392 |g year:2024 |g day:16 |g month:03 |g pages:117523 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.atherosclerosis.2024.117523 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 392 |j 2024 |b 16 |c 03 |h 117523 | ||